another us biostock anayst knows potential, page-5

"Although his last reply was not in Prima's favour you still posted it,thanks for being honest. Cheers"

yes David Miller's exact words regarding my suggestion back then that Prima Biomed has a good chance of being the next Dendreon, were:

"It's an interesting approach. I'm not aware of anyone who has succeeded in creating in-vivo viable DCs by cloning them. Dendreon, JNJ, Genentech, and others failed. Perhaps Prima does have the tech, but it is a significant difference between this technology and
Dendreon's.

Also, using late-stage patients outside of prostate cancer is a deduction of points, not an addition. This is especially true in ovarian cancer. The need is great, but we catch most women very late.
That said, Dendreon is also trying their next drug in ovarian (and bladder) though both in earlier stages of the disease.
I looked at Prima's latest investor presentation from their web site.
I think I've met someone from management at a conference event.
Thanks for the tip and good luck with the investment,

David"